Tyme Technologies Stock Price

-0.03 (-2.7%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Tyme Technologies Inc New TYME NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.03 -2.7% 1.08 11:31:51
Open Price Low Price High Price Close Price Prev Close
1.10 1.07 1.109 1.11
Bid Price Ask Price Spread News
1.08 1.09 0.01 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
447 181,499 $ 1.09 $ 197,288 - 0.85 - 4.99
Last Trade Time Type Quantity Stock Price Currency
11:31:53 60 $ 1.08 USD


Draw Mode:

Tyme Technologies Inc New Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 185.98M 172.21M 124.52M $ - $ - -0.22 -5.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -755.19k 28.30%

more financials information »

Tyme Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TYME Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.101.13991.021.07690,028-0.02-1.82%
1 Month1.301.351.01231.211,510,372-0.22-16.92%
3 Months1.531.751.01231.382,779,911-0.45-29.41%
6 Months1.974.991.01232.576,746,974-0.89-45.18%
1 Year1.304.990.852.393,976,910-0.22-16.92%
3 Years2.904.990.852.291,678,645-1.82-62.76%
5 Years4.49479.500.852.351,324,028-3.41-75.97%

Tyme Technologies Description

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Your Recent History
Tyme Techn..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.